EndoC-βH5®
Five versions to become fully similar to native human pancreatic beta cells
NO COMPROMISE NEEDED: WHEN DATA REPRODUCIBILITY AND CELL FUNCTION ROBUSTNESS ARE NO LONGER A DREAM
EndoC-βH5® is a ready-to-use, > 99% pure population of functional human pancreatic beta cells, and totally comparable to primary human beta cells
EndoC-βH5® cells physiological and functional characteristics are highly similar to those of native human pancreatic beta cells. They represent an invaluable tool to better understand human beta cell physiology, function, proliferation and apoptosis, and a major improvement compared to previous EndoC-βH versions and other beta cell models. EndoC-βH5® cells display robust GLP-1 and GIP receptor activity associated with insulin content and glucose stimulated insulin secretion levels, close to those of native human beta cells.
Take the best – Ignore the rest
EndoC-βH5® cells take the best out of native human beta cells with high sensitivity to physiological concentrations of glucose and robust response to insulin secretagogues and ignore the rest, thanks to complete data reproducibility, ready to use format that eliminates time consuming cell preparations, access to large batches of cells, batch to batch validated reproducibility and ability to maintain stable function for weeks
ALREADY TESTED AND APPROVED BY MORE THAN
Academic & pharmaceutical laboratories worldwide
NEED TO GO ONE STEP FURTHER?
Our Human Cell Design team of experts develops assays and provides you with tailored EndoC-βH5® cell models.
KEY BENEFITS
APPLICATIONS
TECHNOLOGY LIMITS
QUALITY ASSURANCE
Deposited cell line (Pasteur Institute CNCM)
Functional validation (glucose and incretin)
Batch Release Certificates available
Negative for mycoplasma
FUNCTIONAL VALIDATION
Glucose stimulated insulin secretion (GSIS)
EndoC-βH5® cells very efficiently secrete insulin in response to glucose (20mM) and low concentration of GLP1R agonist Exendin-4 (1nM). EndoC-βH5® cell doses dependently respond to physiological concentrations of glucose (maximum response between 5,5 and 11mM Glucose).
Pharmacological validation
EndoC-βH5® cell doses dependently respond to incretin analogs Exendin-4, an agonist of GLP1 receptor (left panel), and [D-Ala2]-GIP, an agonist of GIP receptor (right panel).
Model robustness
EndoC-βH5® cells maintain stable responses to glucose and GLP1R agonist Exendin-4 for 4 weeks post thawing and seeding (left panel). GSIS in EndoC-βH5® cells can be performed in 96-well plates, thus reducing the required amount of cells for a given experiment (right panel).
